Suneva Medical Announces An Expansion Of Its ReGenica® Distribution Partnership With Obagi Medical Products
SANTA BARBARA, Calif., Oct. 29, 2013 /PRNewswire/ -- Suneva Medical, Inc., a rapidly growing medical aesthetics company, announced today plans to expand its existing partnership with Obagi Medical Products, Inc. (Obagi).
Suneva Medical distributes, and is the exclusive licensee for, the full line of ReGenica® skincare products, and Obagi currently co-distributes ReGenica Facial Rejuvenation Complex. Under the terms of the existing agreement between the two companies, Obagi will now co-distribute ReGenica Advanced Rejuvenation Day Repair and ReGenica Advanced Rejuvenation Overnight Repair.
"Obagi has done an excellent job penetrating the marketplace with the technologically advanced ReGenica growth factor product. We look forward to working together with Obagi to expand this innovative skincare line," stated Nicholas Teti, Chairman and Chief Executive Officer of Suneva Medical.
The ReGenica Day Repair and Overnight Repair products represent the next generation of growth factor skincare technology, containing a unique combination of multipotent cell-derived growth factors known to help revitalize and rejuvenate the appearance of skin.
ReGenica was developed by Histogen, Inc.'s Chief Executive Officer and Chairman, Dr. Gail K. Naughton, a leading scientist in the field of regenerative medicine. The ReGenica product line contains Multipotent Cell Conditioned Media (CCM) Complex, which has a variety of stem cell proteins and growth factors that are characteristic of young, rapidly developing tissue and are associated with skin rejuvenation and repair. Only ReGenica contains this breakthrough, animal-free, concentrated formulation that contains the most advanced cosmeceutical skin conditioning agents. The ReGenica product line is exclusively physician-dispensed, available for purchase in dermatology, plastic surgery and other physician practices.
About Suneva Medical, Inc.
Suneva Medical, Inc. is a privately-held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the general dermatology and aesthetic markets. The company currently markets ArteFill®, ReFissa® and ReGenica® Skincare in the U.S. and Bellafill® in Canada. Additionally, ArteFill is available in several international markets, including South Korea and Singapore. For more information, visit www.sunevamedical.com.
ReGenica® is a trademark of Histogen, Inc., exclusively licensed to Suneva Medical, Inc. The Multipotent Cell Conditioned Media Complex is covered by US patents #8,257,947 and #8,524,494.
SOURCE Suneva Medical, Inc.